Detalhe da pesquisa
1.
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Proc Natl Acad Sci U S A
; 119(21): e2200413119, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576468
2.
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Ann Rheum Dis
; 79(6): 837-839, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32332072
3.
Drug-Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
J Clin Med
; 12(22)2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38002732
4.
Infliximab for the Treatment of Inflammatory Labyrinthitis: A Retrospective Cohort Study.
J Clin Med
; 12(13)2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37445384
5.
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
J Exp Med
; 220(1)2023 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342455
6.
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies.
Res Sq
; 2022 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35043109
7.
D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients.
Viruses
; 13(5)2021 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33926038
8.
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Sci Immunol
; 6(62)2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34413139
9.
Systemic Type I IFN Inflammation in Human ISG15 Deficiency Leads to Necrotizing Skin Lesions.
Cell Rep
; 31(6): 107633, 2020 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402279